Dilbir Singh Bindra

7851502, Dec 14, 2010

Mar 21, 2008

12/053442

Dilbir S. Bindra - New Brunswick NJ, US
Mandar V. Dali - New Brunswick NJ, US
Prakash V. Parab - New Brunswick NJ, US
Jatin M. Patel - New Brunswick NJ, US
Li Tao - New Brunswick NJ, US
Ravindra W. Tejwani - New Brunswick NJ, US
Nipa Vatsaraj - New Brunswick NJ, US
Yongmei Wu - New Brunswick NJ, US

Bristol-Myers Squibb Company - Princeton NJ

A61K 31/351
A61P 3/10

514460, 424451

Pharmaceutical formulations are provided which are in the form of capsules or tablets for oral use and which include a medicament dapagliflozin or its propylene glycol hydrate.

8221786, Jul 17, 2012

Nov 18, 2010

12/949473

Dilbir S. Bindra - New Brunswick NJ, US
Mandar V. Dali - New Brunswick NJ, US
Prakash V. Parab - New Brunswick NJ, US
Jatin M. Patel - New Brunswick NJ, US
Li Tao - New Brunswick NJ, US
Ravindra W. Tejwani - New Brunswick NJ, US
Nipa Vatsaraj - New Brunswick NJ, US
Yongmei Wu - New Brunswick NJ, US

Bristol-Myers Squibb Company - Princeton NJ

A61K 9/48
A61K 31/70
A61K 9/30
A61P 3/00
A61P 9/00

424452, 514 23, 514460, 424465, 424451

Pharmaceutical formulations are provided which are in the form of capsules or tablets for oral use and which include a medicament dapagliflozin or its propylene glycol hydrate.

8361972, Jan 29, 2013

Jun 21, 2012

13/529463

Dilbir S. Bindra - New Brunswick NJ, US
Mandar V. Dali - New Brunswick NJ, US
Prakash V. Parab - New Brunswick NJ, US
Jatin M. Patel - New Brunswick NJ, US
Li Tao - New Brunswick NJ, US
Ravindra W. Tejwani - New Brunswick NJ, US
Nipa Vatsaraj - New Brunswick NJ, US
Yongmei Wu - New Brunswick NJ, US

Bristol Myers-Squibb Company - Princeton NJ

A61K 9/48
A61K 31/70
A61K 9/30
A61P 3/00
A61P 9/00

514 23, 424452, 424465, 424451, 514460

Pharmaceutical formulations are provided which are in the form of capsules or tablets for oral use and which include a medicament dapagliflozin or its propylene glycol hydrate.

20130039989, Feb 14, 2013

Apr 29, 2011

13/643561

Dilbir S. Bindra - New Brunswick NJ, US
Yeshwant Gokhale - New Brunswick NJ, US
Cletus John Nunes - New Brunswick NJ, US
Victor W. Rosso - New Brunswick NJ, US
Gretchen M. Schroeder - Princeton NJ, US
Ajit B. Thakur - East Brunswick NJ, US
Xiaotian Yin - New Brunswick NJ, US

A61K 31/444
A61P 35/00
C07D 401/12
A61K 9/14

424490, 514335, 546261

Disclosed are salts and crystalline forms of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide and salts thereof. Also disclosed are at least one pharmaceutical composition comprising at least one crystalline form of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide, at least one method of using at least one crystalline form of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide to treat cancer and/or other proliferative diseases, and processes to prepare crystalline forms of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide and salts thereof.

20130296325, Nov 7, 2013

Jan 13, 2012

13/979174

Ajit S. Narang - Monmouth Junction NJ, US
Sherif Ibrahim Farag Badawy - Dayton NJ, US
Ganeshkumar A. Subramanian - Piscataway NJ, US
Keirnan Ryan LaMarche - Helmetta NJ, US
Dilbir S. Bindra - Hillsborough NJ, US
Venkatramana M. Rao - Edison NJ, US

Bristol-Myers Squibb Company - Princeton NJ

A61K 9/20
A61K 31/53

514243

The present invention is directed to a high drug load tablet formulation of [(1R),2S]-2-aminopropionic acid 2-[4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]-1-methylethyl ester, and to methods of using the formulation in the treatment of cancer. The tablet is obtained by means of a wet granulation process.

51654075, Nov 24, 1992

Apr 9, 1991

7/682560

George S. Wilson - Lawrence KS
Dilbir S. Bindra - Lawrence KS
Brian S. Hill - Lawrence KS
Daniel R. Thevenot - Paris Cedex, FR
Robert Sternberg - Thiais, FR
Gerard Reach - Paris Cedex, FR
Yanan Zhang - Lawrence KS

The University of Kansas - Lawrence KS

A61B 500

128635

Implantable enzymatic sensors (25, 43, 44) for biochemicals such as glucose are provided having an ideal size and geometry for optional long term implantation and linear responses over the concentration ranges of interest. The sensors (25, 43, 44) include an elongated body (10, 26, 46) supporting an indicating electrode section having an appropriate enzyme immobilized thereon to present an enzymatic indicating surface (21, 33, 54). A permeable synthetic polymer membrane (24, 42, 56) is applied over the sensor body (10, 26, 46) to protect the enzyme and regulate diffusion of analyte therethrough, to ensure linearity of sensor response. The sensors (25, 43) are of flexible design and can be implanted using a catheter. Alternately, the sensor (44) includes an internal indicating electrode body (46) housed within an apertured, hollow needle (48). A holder (66) affixed to the needle (48) allows for easy manipulation and implantation of the sensor (44).

20150297603, Oct 22, 2015

Jun 30, 2015

14/755143

- Princeton NJ, US
Sherif Ibrahim Farag Badawy - Dayton NJ, US
Ganeshkumar A. Subramanian - Piscataway NJ, US
Keirnan Ryan LaMarche - Helmetta NJ, US
Dilbir S. Bindra - Hillsborough NJ, US
Venkatramana M. Rao - Edison NJ, US

A61K 31/53
A61K 9/20

The present invention is directed to a high drug load tablet formulation of [(1R), 2S]-2-aminopropionic acid 2-[4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]-1-methylethyl ester, and to methods of using the formulation in the treatment of cancer.

20150119317, Apr 30, 2015

May 3, 2013

14/399114

- Princeton NJ, US
Preetanshu Pandey - Piscataway NJ, US
Dilbir S. Bindra - Hillsborough NJ, US
Chandra Vemavarapu - Hillsborough NJ, US
Robert Kevin Perrone - Belle Mead NJ, US

A61K 38/06
A61K 31/355

514 38, 514 219

The present invention is directed to an oral solid dosage formulation of Asunaprevir, 1,1-dimethylethyl[(1S)-1-{[(2S,4R)-4-(7-chloro-4methoxyisoquinolin-1-yloxy)-2-({(1R,2S)-1-[(cyclopropylsulfonyl)carbamoyl]-2-ethenylcyclopropyl}carbamoyl)pyrrolidin-1-yl]carbonyl}-2,2-dimethylpropyl]carbamate, and to methods of using the formulation in the treatment and/or inhibition of the hepatitis C virus and infections caused thereby.